CytoDel is a startup. Brouky records 1 investor associated with the company.
CytoDel is a biopharmaceutical company that uses recombinant molecular biology techniques to produce customized derivatives of botulinum neurotoxin for specific applications.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.